2016, Volume 23, Supplement 1: Perspectives in chronic heart failure – new treatment advances

Introduction

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

Introduction

Heart failure is a leading cause of morbidity and mortality and presents many treatment challenges. Its prognosis is poor yet many patients do not receive...
Neurohumoral activation in heart failure and the implications for treatment

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

Neurohumoral activation in heart failure and the implications for treatment

The pathophysiology of heart failure is complex. This article describes the neurohumoral pathways that are active in chronic heart failure with left ventricular systolic dysfunction...
Clinical evidence to support the use of sacubitril/valsartan (LCZ696)

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

Clinical evidence to support the use of sacubitril/valsartan (LCZ696)

PARADIGM-HF was the first study to compare the long-term efficacy and safety of the angiotensin-receptor–neprilysin inhibitor (ARNI), sacubitril/valsartan (previously known as LCZ696), against standard care...
The use of sacubitril/valsartan (LCZ696) in clinical practice

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

The use of sacubitril/valsartan (LCZ696) in clinical practice

Professor John McMurray, the principal investigator in the PARADIGM-HF study, writes about his experience with sacubitril/valsartan (known as LCZ696 at the time of the study)...
A comment from primary care

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

A comment from primary care

Much of the work in reducing the mortality and morbidity from heart failure will be carried out in primary care. Treatment of these patients with...